Literature DB >> 1688798

Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography.

S F Le Grice1, F Grüninger-Leitch.   

Abstract

We have modified an Escherichia coli vector expressing 66-kDa HIV-1 reverse transcriptase (p66) so that it simultaneously expresses this and the pol-coded protease. The twin expression cassette yields high quantities of both reverse transcriptase and protease; however, under these conditions, 50% of the over-expressed p66 reverse transcriptase is processed, resulting in accumulation of large quantities of p66/p51 enzyme. Furthermore, addition of a poly(histidine) affinity label at the amino terminus of the reverse-transcriptase-coding sequence (His-p66) permits a simple, rapid purification of milligram quantities of either p66 or p66/p51 enzyme from a crude lysate by metal chelate affinity chromatography. Purified His-p66 and His-p66/His-p51 reverse transcriptase exhibit both reverse transcriptase and RNase H activity. Purification by metal chelate chromatography of a p66/p51 enzyme wherein only the p66 component is labelled strengthens the argument for the existence of a heterodimer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688798     DOI: 10.1111/j.1432-1033.1990.tb15306.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  135 in total

1.  In vitro evidence for the interaction of tRNA(3)(Lys) with U3 during the first strand transfer of HIV-1 reverse transcription.

Authors:  F Brulé; G Bec; G Keith; S F Le Grice; B P Roques; B Ehresmann; C Ehresmann; R Marquet
Journal:  Nucleic Acids Res       Date:  2000-01-15       Impact factor: 16.971

2.  Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication.

Authors:  M Kameoka; L Rong; M Götte; C Liang; R S Russell; M A Wainberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Inhibition of the integrases of human immunodeficiency viruses type 1 and type 2 by reverse transcriptases.

Authors:  Iris Oz; Orna Avidan; Amnon Hizi
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

4.  Structural and functional properties of the HIV-1 RNA-tRNA(Lys)3 primer complex annealed by the nucleocapsid protein: comparison with the heat-annealed complex.

Authors:  Fabienne Brulé; Roland Marquet; Liwei Rong; Mark A Wainberg; Bernard P Roques; Stuart F J Le Grice; Bernard Ehresmann; Chantal Ehresmann
Journal:  RNA       Date:  2002-01       Impact factor: 4.942

5.  Identification of specific HIV-1 reverse transcriptase contacts to the viral RNA:tRNA complex by mass spectrometry and a primary amine selective reagent.

Authors:  Mamuka Kvaratskhelia; Jennifer T Miller; Scott R Budihas; Lewis K Pannell; Stuart F J Le Grice
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

6.  Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole Analogs.

Authors:  Swastika Ganguly; Sankaran Murugesan; Naru Prasanthi; Onur Alptürk; Brian Herman; Nicolas Sluis-Cremer
Journal:  Lett Drug Des Discov       Date:  2010-06-01       Impact factor: 1.150

7.  Human immunodeficiency virus type-1 reverse transcription can be inhibited in vitro by oligonucleotides that target both natural and synthetic tRNA primers.

Authors:  X Wei; M Götte; M A Wainberg
Journal:  Nucleic Acids Res       Date:  2000-08-15       Impact factor: 16.971

8.  Effect of tRNA on the Maturation of HIV-1 Reverse Transcriptase.

Authors:  Tatiana V Ilina; Ryan L Slack; John H Elder; Stefan G Sarafianos; Michael A Parniak; Rieko Ishima
Journal:  J Mol Biol       Date:  2018-05-08       Impact factor: 5.469

9.  Hydroxyl radical footprint analysis of human immunodeficiency virus reverse transcriptase-template.primer complexes.

Authors:  W Metzger; T Hermann; O Schatz; S F Le Grice; H Heumann
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

10.  Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine.

Authors:  Jeffrey D Meteer; Raymond F Schinazi; John W Mellors; Nicolas Sluis-Cremer
Journal:  Antiviral Res       Date:  2013-11-07       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.